Proton magnetic resonance spectroscopy in a case of subacute sclerosing panencephalitis

被引:8
作者
Kato, Z [1 ]
Saito, K [1 ]
Yamada, M [1 ]
Asano, T [1 ]
Kondo, N [1 ]
机构
[1] Gifu Univ, Sch Med, Dept Pediat, Gifu 5008705, Japan
关键词
D O I
10.1177/08830738020170101809
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Subacute sclerosing panencephalitis is an encephalopathy caused by a persistent measles virus infection. We examined a 13-year-old girl with subacute sclerosing panencephalitis and performed a magnetic resonance spectroscopic study to evaluate the in vivo pathophysiologic abnormality. The results suggested the occurrence of inflammatory processes and glial proliferation prior to neuronal loss even in magnetic resonance imaging (MRI)-negative regions as well as in MRI-positive regions. The additional resonance peaks were also detected, but further studies should be performed to determine the precise pathophysiologic mechanisms. Novel in vivo modalities such as spectroscopy would be useful as a tool to measure responses to therapy.
引用
收藏
页码:788 / 790
页数:3
相关论文
共 6 条
[1]   MRI findings in subacute sclerosing panencephalitis [J].
Anlar, B ;
Saatci, I ;
Kose, G ;
Yalaz, K .
NEUROLOGY, 1996, 47 (05) :1278-1283
[2]  
Danielsen E.R., 1999, MAGNETIC RESONANCE S
[3]  
JABBOUR JT, 1969, J AMER MED ASSOC, V207, P2248
[4]   In vivo cerebral proton MRS in a case of subacute sclerosing panencephalitis [J].
Salvan, AM ;
Confort-Gouny, S ;
Cozzone, PJ ;
Vion-Dury, J ;
Chabrol, B ;
Mancini, J .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1999, 66 (04) :547-548
[5]   Combined treatment with interferon-alpha and ribavirin for subacute sclerosing panencephalitis [J].
Tomoda, A ;
Shiraishi, S ;
Hosoya, M ;
Hamada, A ;
Miike, T .
PEDIATRIC NEUROLOGY, 2001, 24 (01) :54-59
[6]   Effects of vigabatrin intake on brain GABA activity as monitored by spectrally edited magnetic resonance spectroscopy and positron emission tomography [J].
Weber, OM ;
Verhagen, A ;
Duc, CO ;
Meier, D ;
Leenders, KL ;
Boesiger, P .
MAGNETIC RESONANCE IMAGING, 1999, 17 (03) :417-425